图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
国际药用蘑菇期刊
影响因子: 1.423 5年影响因子: 1.525 SJR: 0.431 SNIP: 0.661 CiteScore™: 1.38

ISSN 打印: 1521-9437
ISSN 在线: 1940-4344

国际药用蘑菇期刊

DOI: 10.1615/IntJMedMushrooms.2019030047
pages 105-119

Cancer without Pharmacological Illusions and a Niche for Mycotherapy (Review)

Ivan V. Zmitrovich
Laboratory of Systematics and Geography of the Fungi of the Komarov Botanical Institute of the Russian Academy of Sciences, Prof. Popova St. 2, St. Petersburg, 197376, Russia
Nina V. Belova
Laboratory of Fungal Biochemistry, Komarov Botanical Institute of the Russian Academy of Sciences, 2 Professor Popov St., St. Petersburg 197376, Russia
Mikhail E. Balandaykin
Department of Biology, Ulyanovsk State University, 42 L. Tolstoy St., Ulyanovsk 432017, Russia
Margarita A. Bondartseva
Laboratory of Systematics and Geography of Fungi, Komarov Botanical Institute of the Russian Academy of Sciences, Saint Petersburg, Russia
Solomon P. Wasser
International Centre for Biotechnology and Biodiversity of Fungi Institute of Evolution and Faculty of Natural Sciences University of Haifa, Mt. Carmel, Haifa 31905, Israel

ABSTRACT

In this review we outline a framework in which mycotherapy is effective in the field of oncology. We suppose that irreversible epigenomic changes in cancer cells and achieving their replicative immortality when cancer-specific targets are absent should take away any illusions about a fundamental possibility of pharmacological blockage of the cancer process once ontogenesis begins. At the same time, however, we believe that effects of both traditional and alternative medicines on cancer clonogenic units within a particular range can lead to prolonged remission; with this in mind, we carefully consider the various possibilities of mycotherapy in controlling cancer activity. The aforementioned range is limited to nondisseminated cancer processes and depends on the absence of large secondary tumor nodes and the inexhaustibility of immune depots after chemotherapeutic treatment. The main therapeutic effect of fungal bioactive complexes is dectin-1-mediated immunity, including the reprogramming of dendritic cells, which significantly increases the period during which tumors generate immune tolerance. An inhibitory effect of fungal bioactive complexes on some molecular mediators of proliferative signaling and components of proinflammatory (synergistic with cancer) immunity can be considered less significant. The effect of fungal bioactive complexes on vital (including overexpressed) targets of cancer cells is even more limited. The results of this study stress that mycotherapy is only one of the tools that can be used to balance remission. Palliative mycotherapy is associated with polyphenols composites, which contribute to detoxification and to the suppression of inflammation and pain sensation.